Syndax Pharmaceuticals Förvaltning
Förvaltning kriterier kontrolleras 3/4
Syndax Pharmaceuticals VD är Michael Metzger, utsedd i Feb 2022, har en mandatperiod på 4.42 år. totala årliga ersättningen är $ 7.09M, bestående av 10.6% lön 89.4% bonusar, inklusive företagsaktier och optioner. äger direkt 0.071% av företagets aktier, värda $ 1.45M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 4.1 år respektive 10 år.
Viktig information
Michael Metzger
Verkställande direktör
US$7.1m
Total ersättning
| VD-lön i procent | 10.64% |
| Anställning som VD | 4.4yrs |
| Ägande av VD | 0.07% |
| Ledningens genomsnittliga anställningstid | 4.1yrs |
| Styrelsens genomsnittliga mandatperiod | 10yrs |
Senaste uppdateringar av ledningen
Recent updates
Seeking Alpha • 7h
A Fresh Look At Syndax Pharmaceuticals
Summary Syndax Pharmaceuticals is leveraging first-mover advantage and broad label approval for Revuforj to approach profitability despite recent revenue misses. SNDX's near-term catalysts include pivotal Phase 2/3 data for Niktimvo in 1L cGvHD and IPF, expected in 4Q26 and 2H26, respectively. Sell-side consensus remains bullish unaminous buy ratings from the analyst firm community which forecasts profitability in FY2028 and significant revenue growth from pipeline expansion. A fresh analysis on this small cap oncology concern follows in the paragraphs below. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jun 17
SNDX: Acute Leukemia Data And Post Transplant Outcomes May Unlock Upside
The analyst price target for Syndax Pharmaceuticals has shifted modestly, with a blended impact from recent Street updates that include Guggenheim trimming its target to $31 from $34, UBS edging its target to $37 from $38, and other firms making smaller upward and downward revisions based on updated acute myeloid leukemia modeling and commercial commentary around revumenib. Analyst Commentary Recent Street commentary around Syndax Pharmaceuticals highlights a mix of recalibrated models and ongoing conviction in the story around revumenib and the acute myeloid leukemia opportunity.Uppdatering av berättelse • Jun 03
SNDX: Upcoming IPF Phase 2 Data And ASCO Results May Unlock Upside
Analysts have fine tuned their Syndax Pharmaceuticals price targets in a tight range, with moves such as UBS trimming its target to $37 from $38 and JPMorgan lifting its target to $45 from $33. These adjustments reflect updated views on discount rates, revenue growth expectations and future P/E assumptions rather than a wholesale shift in overall fair value estimates.Uppdatering av berättelse • May 20
SNDX: Upcoming IPF Data Readout May Unlock Underappreciated Upside Potential
Analysts have reduced the Syndax Pharmaceuticals fair value estimate from $56.00 to approximately $53.54, reflecting a combination of slightly lower price targets and updated views on growth, profitability, and appropriate P/E levels across recent research updates. Analyst Commentary Recent Street research on Syndax Pharmaceuticals shows a mix of target price increases and reductions, with the overall effect being a modest pullback in the aggregated fair value estimate.Analysartikel • May 05
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) shareholders are probably feeling a little disappointed, since its shares...
Uppdatering av berättelse • Apr 29
SNDX: Upcoming Pulmonary Fibrosis Readout Will Refine Risk Profile And Long-Term Upside
The updated analyst price target for Syndax Pharmaceuticals edges up by about $1 to $39.50 as analysts factor in new Street research that balances recent target cuts with higher targets and fresh Buy initiations. Analyst Commentary Street research on Syndax Pharmaceuticals has been active, with several firms adjusting price targets and ratings in recent weeks.
Uppdatering av berättelse • Apr 14
SNDX: MAXPIRe IPF Data Will Drive Future Upside Versus Execution Risks
The updated analyst price target for Syndax Pharmaceuticals now stands at $28.00. The adjustment is based on recent Street research that weighs higher targets from several firms against more cautious revisions, as analysts reassess the risk profile and potential of the Revuforj and Niktimvo franchises.Uppdatering av berättelse • Mar 31
SNDX: MAXPIRe IPF Readout Will Shape Upside Beyond Core Franchise
Analysts have lifted their blended price target on Syndax Pharmaceuticals to $57, with the change largely tied to updated views on Revuforj and Niktimvo, as well as the upcoming Phase 2 MAXPIRe readout, which some see as an additional call option that is not fully reflected in the current share price. Analyst Commentary Street research on Syndax Pharmaceuticals in recent months has centered on how much value to assign to Revuforj and Niktimvo in existing refractory settings versus the potential upside from the MAXPIRe study in idiopathic pulmonary fibrosis.Uppdatering av berättelse • Mar 17
SNDX: MAXPIRe IPF Readout Will Drive Future Repricing Potential
Analysts have lifted their average price target on Syndax Pharmaceuticals to a range anchored around recent Street moves toward $45 to $57, citing growing conviction in the potential contribution from Revuforj, Niktimvo and upcoming Niktimvo IPF Phase 2 MAXPIRe data, which some view as a "free call option" at current share levels. Analyst Commentary Recent research on Syndax Pharmaceuticals has focused on how much value the market may be assigning to Revuforj and Niktimvo in their current and potential indications, as well as the impact of upcoming Niktimvo idiopathic pulmonary fibrosis data from the Phase 2 MAXPIRe study.Uppdatering av berättelse • Mar 02
SNDX: Leukemia Drug Progress And Citi Upgrade Will Drive Future Repricing
Narrative update on Syndax Pharmaceuticals The analyst fair value estimate for Syndax Pharmaceuticals has shifted from $27.00 to $28.00, supported by recent price target increases from firms such as Citi and BofA as analysts factor in updated expectations for revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent Street research on Syndax Pharmaceuticals has centered on adjustments to price targets and the assumptions behind them, including revenue outlook, profitability, and P/E expectations.Uppdatering av berättelse • Feb 16
SNDX: Expanded Leukemia Reach And Refined Risk Profile Will Support Long-Term Upside
Analysts have nudged their price target on Syndax Pharmaceuticals higher by $1, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as key drivers behind the change. Analyst Commentary Analysts lifting their fair value assumptions on Syndax Pharmaceuticals are generally reacting to updated views on growth, profitability, and risk, which together support the modest US$1 move in the price target.Uppdatering av berättelse • Feb 02
SNDX: FDA Leukemia Progress And UBS Upgrade Will Drive Future Repricing
Narrative Update: Syndax Pharmaceuticals Analysts recently raised their price target on Syndax Pharmaceuticals shares to $38 from $35, citing updated assumptions for growth, profitability, and future P/E that have modestly adjusted their valuation outlook. Analyst Commentary Although the latest price target is now US$38, analysts are not uniformly positive and continue to highlight areas of uncertainty around how that valuation could be realized.Uppdatering av berättelse • Jan 19
SNDX: FDA Decision On Leukemia Therapy Will Drive Future Repricing Potential
Analysts have lifted their fair value estimate for Syndax Pharmaceuticals to US$27.00 from US$19.00. They cite higher Street price targets following recent FDA action on Revuforj and a willingness to use a richer future P/E multiple, even with more conservative assumptions for revenue growth and profit margins.Uppdatering av berättelse • Jan 04
SNDX: Expanded Leukemia Approval Will Support Stronger Long Term Upside Potential
Analysts modestly raised their blended price target for Syndax Pharmaceuticals, reflecting recent upward revisions from $35 to $38 and from $26 to $27, as they point to supportive FDA developments and view recent stock weakness as overdone. Analyst Commentary Bullish analysts highlight that recent price target increases reflect confidence in Syndax Pharmaceuticals' ability to execute on its clinical and commercial strategy, even after market volatility following regulatory updates.Uppdatering av berättelse • Dec 18
SNDX: Expanded Leukemia Approval Will Drive Stronger Long Term Commercial Momentum
Analysts have nudged their average price target on Syndax Pharmaceuticals modestly higher, to about $39.31 per share from roughly $39.31, citing strengthened conviction in long term growth and profitability following supportive regulatory developments and recent target increases from multiple covering firms. Analyst Commentary Recent target increases and reiterated positive ratings underscore a growing confidence among coverage in Syndax Pharmaceuticals, particularly around its lead asset Revuforj and the companys ability to convert regulatory wins into durable revenue growth.Uppdatering av berättelse • Dec 04
SNDX: Expanded Leukemia Label Will Drive Stronger Long Term Commercial Momentum
The analyst price target for Syndax Pharmaceuticals has been raised by approximately $1 to about $39 per share, as analysts cite recent target increases across the Street and reaffirmed Buy ratings, supported by continued confidence in Revuforj's commercial outlook despite label-related concerns. Analyst Commentary Bullish analysts highlight that the recent price target increases, even if modest in absolute dollars, signal growing confidence in Syndax's execution and Revuforj's commercial ramp.Analysartikel • Nov 23
Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Shares Climb 29% But Its Business Is Yet to Catch Up
Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) shares have had a really impressive month, gaining 29% after a shaky...Uppdatering av berättelse • Nov 20
SNDX: New FDA Approval Will Drive Continued Momentum In Oncology Markets
The analyst price target for Syndax Pharmaceuticals has been revised downward by $0.54 to $38.31. Analysts factor in lower projected profit margins and slower revenue growth, despite ongoing industry optimism around the company's recent drug approvals and market positioning.Analysartikel • Nov 06
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results
It's been a pretty great week for Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) shareholders, with its shares surging...Uppdatering av berättelse • Nov 05
SNDX: Recent FDA Approvals Will Expand Market Opportunity In AML Therapy
The analyst price target for Syndax Pharmaceuticals has increased from approximately $36.55 to $38.85. Analysts cite recent FDA approvals and positive strategic developments as key factors supporting the upward revision.Analysartikel • Aug 06
Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking
NasdaqGS:SNDX 1 Year Share Price vs Fair Value Explore Syndax Pharmaceuticals's Fair Values from the Community and...Uppdatering av berättelse • Aug 06
Revuforj And Niktimvo Will Extend Precision Oncology Reach
Despite a sharp reduction in expected revenue growth, Syndax Pharmaceuticals’ future P/E has improved considerably, supporting a higher analyst price target, now revised up from $32.67 to $34.33. What's in the News Syndax Pharmaceuticals announced the FDA has granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj (revumenib) for the treatment of relapsed or refractory mutant NPM1 (mNPM1) acute myeloid leukemia (AML), reviewed under the Real-Time Oncology Review (RTOR) program.Analysartikel • Aug 05
Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • May 08
Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results
Shareholders in Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) had a terrible week, as shares crashed 29% to US$9.99 in...Analysartikel • Apr 26
Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Ny berättelse • Mar 24
FDA Approvals Will Expand AML And cGVHD Treatment Options
Recent FDA approvals and strategic collaborations position Syndax to significantly enhance revenue and address unmet clinical needs in oncology.Analysartikel • Feb 07
Is Syndax Pharmaceuticals (NASDAQ:SNDX) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Jan 22
Syndax Looks Tantalizing, But Looks Can Be Deceptive
Summary Syndax Pharmaceuticals has two approved drugs, Axatilimab and Revumenib, but the stock has fallen 50% due to competitive pressures and market skepticism. Revumenib shows promise in treating KMT2A AML and mNPM1 AML, but faces stiff competition from Kura Oncology's superior efficacy data in mNPM1 AML. Axatilimab, approved for cGVHD, differentiates itself from other treatments but operates in a differentiated market with limited revenue potential. Despite a strong cash position and promising pipeline, market concerns about revenue potential and competition keep SNDX stock depressed. Read the full article on Seeking AlphaAnalysartikel • Oct 14
We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Sep 20
Syndax Pharmaceuticals: Navigating Through A Pivotal Year
Summary Syndax Pharmaceuticals, Inc.'s stock is down 25% from recent highs, presenting a potential buying opportunity for aggressive investors as the company nears key inflection points. The company recently had its first drug it has developed with Incyte approved, and a wholly owned compound should be approved at the tail end of 2024. The stock enjoys strong analyst support, but is likely to raise additional capital in 2025. An updated analysis around Syndax Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaAnalys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$243m |
| Dec 31 2025 | US$7m | US$754k | -US$285m |
| Sep 30 2025 | n/a | n/a | -US$312m |
| Jun 30 2025 | n/a | n/a | -US$335m |
| Mar 31 2025 | n/a | n/a | -US$331m |
| Dec 31 2024 | US$8m | US$715k | -US$319m |
| Sep 30 2024 | n/a | n/a | -US$297m |
| Jun 30 2024 | n/a | n/a | -US$264m |
| Mar 31 2024 | n/a | n/a | -US$241m |
| Dec 31 2023 | US$9m | US$678k | -US$209m |
| Sep 30 2023 | n/a | n/a | -US$176m |
| Jun 30 2023 | n/a | n/a | -US$160m |
| Mar 31 2023 | n/a | n/a | -US$153m |
| Dec 31 2022 | US$4m | US$640k | -US$149m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | US$818k |
| Mar 31 2022 | n/a | n/a | US$15m |
| Dec 31 2021 | US$3m | US$594k | US$25m |
| Sep 30 2021 | n/a | n/a | -US$92m |
| Jun 30 2021 | n/a | n/a | -US$91m |
| Mar 31 2021 | n/a | n/a | -US$86m |
| Dec 31 2020 | US$2m | US$577k | -US$77m |
| Sep 30 2020 | n/a | n/a | -US$71m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$3m | US$540k | -US$56m |
Ersättning vs marknad: Michael s total kompensation ($USD 7.09M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 5.19M ).
Ersättning vs inkomst: Ersättningen från Michael har varit i linje med företagets resultat under det senaste året.
VD OCH KONCERNCHEF
Michael Metzger (55 yo)
4.4yrs
Anställning
US$7,089,213
Kompensation
Mr. Michael A. Metzger is an Independent Director at Pyxis Oncology, Inc since June 10, 2024. Mr. Metzger has experience in the biopharmaceutical sector, is serving as Chief Executive Officer since Februar...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 4.4yrs | US$7.09m | 0.071% $ 1.4m | |
| CFO, Treasurer & Principal Accounting Officer | 4.1yrs | US$2.47m | 0.031% $ 638.7k | |
| Senior VP | 9.9yrs | US$2.33m | 0.15% $ 3.0m | |
| Chief Commercial Officer | 2.3yrs | US$2.13m | 0.14% $ 2.8m | |
| Head of Research & Development and Chief Medical Officer | 1.2yrs | US$3.08m | 0.069% $ 1.4m | |
| Co-Founder & Chief Scientific Officer | 20.8yrs | inga uppgifter | inga uppgifter | |
| Co-Founder | no data | inga uppgifter | inga uppgifter | |
| Co-Founder | no data | inga uppgifter | inga uppgifter | |
| Co-Founder | no data | inga uppgifter | inga uppgifter | |
| Vice President of Investor Relations & Communications | 4.1yrs | inga uppgifter | inga uppgifter | |
| Chief People Officer | 3.2yrs | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board & Chief Medical Officer | 3.6yrs | inga uppgifter | inga uppgifter |
4.1yrs
Genomsnittlig anställningstid
57yo
Genomsnittlig ålder
Erfaren ledning: SNDX s ledningsgrupp anses vara erfaren ( 4.1 års genomsnittlig anställningstid).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 7yrs | US$7.09m | 0.071% $ 1.4m | |
| Co-Founder | 10yrs | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board & Chief Medical Officer | 10yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 9.3yrs | US$511.25k | 0.10% $ 2.1m | |
| Independent Director | 9.5yrs | US$503.75k | 0.10% $ 2.1m | |
| Independent Chairman | 17.6yrs | US$947.00k | 0.20% $ 4.1m | |
| Member of Scientific Advisory Board | 9.3yrs | US$23.05k | inga uppgifter | |
| Member of Scientific Advisory Board | 10yrs | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | 10yrs | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | 10yrs | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | 10.6yrs | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | 9.5yrs | inga uppgifter | inga uppgifter |
10.0yrs
Genomsnittlig anställningstid
66yo
Genomsnittlig ålder
Erfaren styrelse: SNDX s styrelse är rutinerade och erfaren ( 10 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/14 04:43 |
| Aktiekurs vid dagens slut | 2026/07/14 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Syndax Pharmaceuticals, Inc. bevakas av 26 analytiker. 12 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Jason Zemansky | BofA Global Research |